GW Monogram

News - Cloned

  News

Recent Letters from the Director

JulyLFD

The Online GLP-1 Marketplace

The Online GLP-1 Marketplace

July 31, 2026

A recent research letter published in JAMA by Chetty et al describes the experience of a secret shopper in obtaining GLP-1 receptor agonists (GLP-1 RA) from online sources.

June LFD

Understanding PMOS

Understanding PMOS

June 30, 2026

PCOS was recently renamed polyendocrine metabolic ovarian syndrome (PMOS) to address the inadequate treatment that has resulted from its perception as a condition limited to fertility.

May LFD

Lessons from the STOP Obesity Alliance: A Reflection on Obesity Advocacy

Lessons from the STOP Obesity Alliance: A Reflection on Obesity Advocacy

May 29, 2026

This month's author is, Aden Belay, MPH, the STOP Obesity Alliance student research assistant who recently graduated from the Milken Institute School of Public Health.

 

 

 

News Archive

Sep2025_LetterfromDirector

The Relationship between Obesity and the Immune System

This month STOP is exploring a topic that is relatively new to us, the relationship obesity has with immune health.

Aug 2025 Letter from the Director

The Role of Physical Activity in Obesity Treatment

Research has been clear that physical activity should be integrated into both the prevention and comprehensive treatments for obesity.

July 2025 Letter from the Director

Roadmap for Transforming Obesity Disease Management

Last month, the Center for Biomedical System Design (CBSD) program at Tufts Medical Center's Institute for Clinical Research and Health Policy Studies published a comprehensive roadmap for transforming obesity disease management in the United States.

June 2025 Letter from the Director

Guest Letter: Metabolic Health Matters: Addressing Obesity and Advancing Solutions in Fatty Liver Disease

On the second Thursday in June, Global Fatty Liver Day brings overdue attention to one of the most widespread yet overlooked public health threats of our time: fatty liver disease.

May 2025 Letter from Director

Employer Insurance Coverage of Obesity Treatment

Limitations in access and coverage of obesity medications has paralleled the advances in the usage of GLP-1s.

April 2025 Letter from the Director

Guest Letter: Concerns About Compounded GLP-1 Medications

OAC has long advised our members against using compounded GLP-1’s. The main reason is FDA’s own words about compounding.

March 2025 Letter from the Director

FDA's New Draft Guidance for Obesity Medications

This past January the FDA published a draft guidance entitled “Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction.”

Feb 2025 Letter from the Director

Obesity Care Week 2025

OCW's theme this year is “Commit to Care,” to encourage everyone to advocate for accessible, affordable, respectful, and compassionate obesity care.

January 2025 Letter from the Director

Lancet Commission Report on Clinical Obesity

On January 14th, the Lancet Diabetes and Endocrinology Global Commission released a report on the definition and diagnostic criteria of clinical obesity.

December 2024 Letter from the Director”

CMS Proposes Rule to Cover Obesity Medications

In late November, the Centers for Medicare and Medicaid Services (CMS) officially proposed a rule to cover obesity medications in Medicare and Medicaid.

Newsletter icon

Sign up for the monthly STOP Newsletter

Subscribe below to receive STOP's monthly email packed with insights from experts in obesity prevention and treatment, details on upcoming events, and exciting news from our member organizations!

* indicates required

Recent STOP Newsletters